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Summary
Extrapolation from a source to a target, e.g., from adults to children, is a promis-
ing approach to utilizing external information when data are sparse. In the context
of meta-analysis, one is commonly faced with a small number of studies, while
potentially relevant additional information may also be available. Here we describe
a simple extrapolation strategy using heavy-tailed mixture priors for effect estima-
tion in meta-analysis, which effectively results in a model-averaging technique. The
described method is robust in the sense that a potential prior-data conflict, i.e., a dis-
crepancy between source and target data, is explicitly anticipated. The aim of this
paper is to develop a solution for this particular application, to showcase the ease
of implementation by providing R code, and to demonstrate the robustness of the
general approach in simulations.
KEYWORDS:
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1 INTRODUCTION
When empirical evidence is sparse, it may be useful to be
able to utilize related source data to extrapolate to the tar-
geted population. This is especially relevant in the context
of rare diseases or small populations, but the problem is
common in many applications. Several regulatory guidelines
touch upon the problem from different angles, either explic-
itly concerning extrapolation1 and the use of external data2,
or, for example, in the contexts of small populations research3,
paediatric studies4, or bridging studies5. The potential ben-
efits of extrapolation approaches are generally recognized6,7,
especially in the context of rare diseases8,9. Concerning the
methodological aspect, the use of Bayesian methods has fre-
quently been suggested3,10,11,4,12 and also in practice appears
to be the predominant approach13.
In a Bayesian model, external evidence may be considered
e.g. via the formulation of informative priors or the use of hier-
archical models4,13,14,15. As the term extrapolation suggests,
0Abbreviations: AR, acute rejection; CI, credible interval; MAC, meta-
analytic-combined;MAP, meta-analytic-predictive; NNHM, normal-normal hierar-
chical model; OR, odds ratio
there is usually some doubtwhether or to what extent the exter-
nal data can or should be taken at face value and are directly
applicable to the given context. Consequently, the implemen-
tation of (potential) downweighting of the external evidence is
a common requirement13,16.
So far, the literature very much focussed on the setting of
a single target study, but extrapolation may also be useful
in evidence synthesis. Meta-analyses are commonly based on
only few studies, especially when they are concerned with rare
diseases17,18, but also quite generally19,20,21. Additional exter-
nal data may here easily be utilized by the formulation of an
informative prior distribution10,12,11. In the following we intro-
duce the implementation of some degree of scepticism and
robustness by using a heavy-tailed mixture prior22,23,24. Com-
putationally, a mixture prior then results in a model-averaging
technique25. Besides the interpretation of a “robustified” infor-
mative prior distribution, this setup may also be thought of as
a combination of several data models, corresponding to sub-
groupings of the data into studies with common or unrelated
effects26.
Encouraged e.g. by the International Rare Diseases
Research Consortium (IRDiRC)7, the aim of this paper is to
showcase the potential of robust extrapolation in Bayesian
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meta-analysis via prior specification as suggested by Schmidli
et al.24, and to exemplify the relative ease of implemen-
tation and computation. The general idea is actually more
widely applicable, beyond the context of meta-analysis. We
first decribe the general methodology in Sec. 2, and then apply
the approach in two case studies ofmeta-analyses extrapolating
from external source data (adolescents or adults) to children
in applications in asthma and liver transplantation in Sec. 3
and 4. In Sec. 5, the method’s long-run behaviour is inves-
tigated in a small simulation study. Sec. 6 closes with some
concluding remarks. Computations are performed using R and
the bayesmeta and rjags packages27,28,29. Example R code
is available in the Appendix.
2 BAYESIAN RANDOM-EFFECTS
META-ANALYSIS
2.1 The model
Meta-analyses are commonly performed using the normal-
normal hierarchical model (NNHM); the model may be spec-
ified as follows. A number 푘 of studies or measurements 푌푖
(푖 = 1,… , 푘) are given; these measurements only come
with limited accuracy, as expressed by the associated stan-
dard errors 푠푖. We assume that a measurement comes about
as a draw from a normal distribution centered around the
(study-specific) mean 휃푖:
푌푖 | 휃푖 ∼ N(휃푖, 푠2푖 ). (1)
The standard errors are commonly assumed known. The study-
specific means are not necessarily identical across studies,
rather one allows for a certain amount of heterogeneity between
studies, implemented in terms of an additional variance com-
ponent 휏 ≥ 0:
휃푖 |휇, 휏 ∼ N(휇, 휏2) (2)
30,31,32,33. Since often primary interest lies in the overall
effect 휇 (and not in the shrinkage estimates of 휃푖), the model
may be simplified to the marginal form
푌푖 |휇, 휏 ∼ N(휇, 푠2푖 + 휏2). (3)
There are two unknowns that one may want to infer from the
data; the heterogeneity 휏, which commonly constitutes a nui-
sance parameter, and the effect 휇, which is usually of primary
interest. In order to infer the parameters within a Bayesian
framework, one needs to specify prior distributions for휇 and 휏.
2.2 Informative priors and robustness
In the random-effects meta-analysis model we may facilitate
extrapolation by propagating information through the analy-
sis via the prior probability distribution10,12,13. We may have
information from external sources available that can be used
to inform the analysis. However, it is often uncertain whether
this information is directly applicable to the present context or
whether the possibility of an alternative model should also be
considered16,24. Both the utilization of additional information
as well as the explicit consideration of uncertainty may also be
particularly desirable in regulatory decision-making2,34.
A simple way to implement a certain amount of scepti-
cism is via two prior components, which are combined to
form the prior distribution as a mixture13,16,35. To that end
we may formulate two parameter models, 푀푎 and 푀푏, rep-
resenting the cases of equal effects for source and target data
(where direct extrapolation would be valid), and of a differ-
ent, unrelated effect for the new data. The two models simply
differ by their assumed prior for the parameters, 푝(휇, 휏|푀푎)
and 푝(휇, 휏|푀푏), respectively; the associated data model and
likelihood (푝(푦|휇, 휏)) are identical under both models. Both
parameter models have prior probabilities 푝(푀푎) ∈ [0, 1] and
푝(푀푏) = 1 − 푝(푀푎) associated. The marginal prior density
then results as
푝(휇, 휏) = 푝(휇, 휏|푀푎) 푝(푀푎) + 푝(휇, 휏|푀푏) 푝(푀푏) (4)
where the two components now are chosen such that
푝(휇, 휏|푀푎) is informative (with probability concentrated
according to the external information), while 푝(휇, 휏|푀푏) is
vague. The probability 푝(푀푎) then reflects the certainty (or
scepticism) associated with the external information. The same
approach is readily generalized to more than two components;
in the following, we will be concerned with the case of four
parameter models (푀1,… ,푀4) that are associated with prior
probabilities 푝(푀1),… , 푝(푀4) with
∑
푖 푝(푀푖) = 1.
A setup like this results in a heavy-tailed prior compared to
푝(휇, 휏|푀푎) alone; such priors have favourable properties when
the data in fact do turn out to be in conflict with the prior infor-
mation as supplied by 푝(휇, 휏|푀푎) and so it will provide more
robust inference in case of a prior/data conflict23,24.
2.3 Mixture priors and inference
A simple mixture setup has the advantage that it simplifies
computations; the (conditional) posteriors under the two mod-
els 푀푎 and 푀푏 may be computed separately, and the partial
results thenmay be re-combined via their associated Bayes fac-
tors36,24. With that, the mixture prior effectively results in a
model-averaging approach. The simplicity may be seen from
the derivation via Bayes’ theorem. Consider the generic case
of inferring parameters 휗 from data 푦, where the prior 푝(휗)
is given as a two-component mixture distribution analogous
to (4); the parameters’ posterior distribution is given by
푝(휗|푦) = 푝(휗|푦,푀푎) 푝(푀푎|푦) + 푝(휗|푦,푀푏) 푝(푀푏|푦) (5)
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(the detailed derivation is shown in the appendix). So, from
(5) one can see that with the prior set up as a two-component
mixture, the posterior 푝(휗|푦) again is a mixture of the two (con-
ditional) posteriors (푝(휗|푦,푀푎) and 푝(휗|푦,푀푏)). The weight-
ing results from the posterior probabilities for the two model
components (푝(푀푎|푦) and 푝(푀푏|푦)) which again depend on
the marginal likelihoods (푝(푦|푀푎) and 푝(푦|푀푏)) and the prior
probabilities 푝(푀푖):
푝(푀푎|푦) =
푝(푦|푀푎) 푝(푀푎)
푝(푦|푀푎) 푝(푀푎) + 푝(푦|푀푏) 푝(푀푏)
(6)
where the marginal likelihoods are given by
푝(푦|푀푖) = ∫ 푝(푦|휗,푀푖) 푝(휗|푀푖) d휗 (7)
(where 푖 ∈ {푎, 푏}). The approach is analogously generalized
to the case of more than two mixture components.
The posterior distribution may be expressed as a mixture or
weighted average of posterior components, placing the model
in the class ofmodel averaging approaches25,36,37,38. The setup
may be thought of as a combination of several plausible data
models 푀푖. In this particular case, the models under con-
sideration correspond to subgroups of the data into studies
with common or unrelated parameters26. In contrast to model
selection, instead of singling out a particular model for infer-
ence, model averaging then allows to perform unconditional
inference by marginalizing over the uncertain model indicator.
The model averaging setup considers a discrete set of
potential data models. The problem could alternatively be
approached in different ways, for example, by adding further
hierarchical stages to the model, which may then allow to
encompass the same set of models as special cases. Conceptu-
ally, this would replace the “binary” alternatives (of exchange-
able or unrelated data) by a more “continuous” notion of data
similarity.
It is important to note that, due to the dependence on
marginal likelihoods above, the exact specification of the
“vague” prior component is crucial. The problem is related
to Lindley’s paradox 39: Although different vague priors may
differ little in the posterior distributions they imply for the
parameter vector 휗, they may still have a substantial effect on
the corresponding marginal likelihoods (푝(푦|푀푖)), and with
that, the eventual relative weighting of the two conditional
posteriors via 푝(휗|푦,푀푖). The effect may lead to somewhat
counterintuitive behaviour here. While a larger prior variance
for the vague model component may at first seemmore conser-
vative, it may in fact amplify the informative component’s pos-
terior probability by reducing the marginal likelihood under
the vague component.
2.4 Meta-analysis using mixture priors
2.4.1 Meta-analysis of log-ORs
In the following we will conduct meta-analyses using the
random-effects model described in Sec. 2.1 with a mixture
prior as described in Sec. 2.2 and 2.3. The endpoint of inter-
est in the following is a logarithmic odds ratio (log-OR). Odds
ratios and their standard errors on the logarithmic scale are
computed using standard formulas31,32. Themixture prior then
is defined using components that imply different amounts or
pathways of borrowing of information.
The target data set of primary interest consists of 푘T effect
estimates 푌푡,1,… , 푌푡,푘T and standard errors 푠푡,1,… , 푠푡,푘T .
Another set of 푘S additional source estimates and standard
errors (푌푠,푖, 푠푠,푖) is available, which constitutes the potentially
relevant external information.
2.4.2 Prior information and data pooling
Schmidli et al.24 pointed out that in the meta-analysis con-
text consideration of external informationmay be implemented
in two obvious ways. Firstly, in the meta-analytic-combined
(MAC) approach, both source and target data sets are ana-
lyzed jointly. Alternatively, onemay perform an analysis of the
source data to derive an informative meta-analytic-predictive
(MAP) prior distribution for the target data.
Both MAC and MAP approaches can be shown to be equiv-
alent, since performing separate analyses and using one result
to form the prior for the other (MAP approach) yields identi-
cal results to a pooled analysis (MAC approach)24. This has
the advantage of making the flow of information through the
analysis transparent, and it also may be utilized to simplify
computations. Use of an informative prior (based on source
data) may then technically also be viewed as a “pooling” of
source and target data.
2.4.3 Vague prior
The vague prior (푝(휇, 휏|푀4) in the following) is specified as
uninformative, covering a range of a priori plausible values. In
the following, we represent an uninformative prior by a zero-
mean normal distribution with standard deviation 2 for the
effect 휇, and a half-normal distribution with scale 0.5 for the
heterogeneity 휏. For the effect this implies a probability distri-
bution symmetric around zero (corresponding to an odds ratio
of 1) with a 95% prior probability for the log-odds ratio 휇 to lie
within ±3.92, which translates to odds ratios roughly within a
range from 1
50
to 50. This prior may be interpreted as equiv-
alent to the information given by a contingency table of an
effective sample size of 4 patients40. For the heterogeneity, the
half-normal prior also constitutes a conservative choice in the
context of log-OR endpoints33,17,18.
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2.4.4 Mixture prior components
The informative prior components (푝(휇, 휏|푀푖), 푖 < 4) are
specified based on the posterior of a previous, separate
meta-analysis, reflecting the corresponding information. This
previous meta-analysis is again conducted using the vague
prior 푝(휇, 휏|푀4).
Considering the relationship between source and target data
sets, a range of scenarios is conceivable; here we concentrate
on a few simple possibilities. Firstly, the two data sets may be
completely unrelated, so that we have two pairs of parameters
(휇S/휏S and 휇T/휏T), and by analyzing one data set we cannot
learn anything about the other set’s parameters. On the other
hand, effect and heterogeneity may be identical in both popu-
lations (휇T = 휇S and 휏T = 휏S), so that we can pool the data
(MAC approach), or equivalently, use the posterior from one
analysis as the prior for the other (MAP approach). It may also
be possible that only the effect or only the heterogeneity param-
eter are shared between the two populations. For the analysis
of target data, this results in four possible models:
• 푀1: 휇T = 휇S, 휏T = 휏S
(informative prior for 휇T and 휏T; “complete pooling”)
• 푀2: 휇T = 휇S, 휏T ≠ 휏S
(informative prior for 휇T only; “effect pooling”)
• 푀3: 휇T ≠ 휇S, 휏T = 휏S
(informative prior for 휏T only; “heterogeneity pooling”)
• 푀4: 휇T ≠ 휇S, 휏T ≠ 휏S
(vague prior; “standalone analyses”)
These four (conditional) parameter models are associated with
prior probabilities 푝(푀푖).
The eventual model setup then includes the specification
of the vague prior component (푝(휇, 휏|푀4)), and of the prior
probabilities for the four model components 푀푖. Some of the
model probabilities 푝(푀푖) may be set to zero, especially for
components 2 or 3.
While the parameter models 푀1 and 푀4 may be very
obvious, reflecting the commonly faced choice between data
pooling and separate analyses, the other two models deserve
some more consideration. Model 푀3 supports the analysis of
target data by only informing the heterogeneity prior based on
the source data, an approach that is familiar from previous pro-
posals41,42. Model 푀2 is technically similar, but the scenario
may be harder to motivate: a case in which the main effect is
identical, but the heterogeneity is different may not be very
realistic. Also, the relative similarity of models 푀1 and 푀2
as well as 푀3 and 푀4 especially in the context of relatively
few observations (small 푘S and 푘T) may be an argument in
favour of a sparser model not necessarily considering all four
components.
2.5 Computation
Inference within the NNHM may technically be approached
in different ways, for example using stochastic integration via
MCMC methods. In the following we will utilize the rjags29
and bayesmetaR packages28,40. Use of the bayesmeta pack-
age simplifies computations, but it is only applicable for a
subset of models (namely those with 푝(푀2)=0).
3 PAEDIATRIC MIGRAINE CASE STUDY
3.1 Background
The data considered in the following are due to the system-
atic review by Richer et al.43, reporting on the evidence on
the effect of pharmacological medications for the treatment of
acute migraine attacks in children and adolescents. Among the
analyses performed is a comparison of the effect of triptans
(vs. placebo) on the proportion of patients reporting headache
relief. While 20 studies were found quoting odds ratios for
the effect in adolescents (12–17 years of age), only 3 studies
reported on headache relief in children (<12 years of age). The
relevant data (numbers of cases and events, and the derived
ORs) are reproduced in Tab. B1 in the appendix, the effect
sizes are also illustrated in Fig. 1 .
Now suppose we are interested in estimating the effect in
children. Three studies constitute only a small data basis on
which to judge efficacy17, and indeed, a meta-analysis of the
three studies fails to yield a conclusive result; while the odds
ratio is estimated at 1.739 (a beneficial effect), the credible
interval ([0.787,4.461]) is verywide and still includes a neutral
effect of 1.0. It would be desirable if the additional adolescent
studies could possibly be used to clarify whether a clinically
relevant effect is present or not. In order to summarize the
evidence from the adolescent studies, we can perform a meta-
analysis using the vague prior from Sec. 2.4.3, which yields an
estimate and 95%CI for the OR in adolescents of 1.350 [1.069,
1.711].
3.2 Analysis setup
In the present example there is a small number of target stud-
ies that are of primary interest (3 paediatric studies), and in
addition there is another set of potentially relevant additional
source studies available (20 studies performed in adolescent
patients). The additional data provide external information, but
it is not evident a priori to what extent these are directly com-
parable and whether extrapolation is valid. It may be plausible
that the distinction between age groups is somewhat arbitrary,
and that the effect (휇) is indeed the same (or at least very sim-
ilar) in both age groups. This uncertainty is reflected in the
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publication
Hämäläinen (1997b)
Rothner (1997)
Winner (1997)
Rothner (1999a)
Rothner (1999b)
Rothner (1999c)
Winner (2000)
Winner (2002)
Ahonen (2004)
Visser (2004a)
Ahonen (2006)
Evers (2006)
Rothner (2006)
Winner (2006)
Callenbach (2007)
Lewis (2007)
Winner (2007)
Linder (2008)
Ho (2012)
Fujita (2014)
  adolescents only
Ueberall (1999)
Hämäläinen (2002)
Ho (2012)
  children only
  children combined
subjects
adolescents
adolescents
adolescents
adolescents
adolescents
adolescents
adolescents
adolescents
adolescents
adolescents
adolescents
adolescents
adolescents
adolescents
adolescents
adolescents
adolescents
adolescents
adolescents
adolescents
children
children
children
OR
1.575
0.609
1.375
0.747
1.241
0.841
1.603
1.489
2.816
0.977
4.950
4.295
0.866
1.355
1.454
1.703
0.904
1.923
1.350
0.718
1.350
8.000
2.563
0.930
1.739
1.402
95% CI
[0.416, 5.959]
[0.356, 1.042]
[0.813, 2.326]
[0.356, 1.567]
[0.451, 3.420]
[0.363, 1.947]
[1.070, 2.401]
[0.927, 2.392]
[1.501, 5.282]
[0.663, 1.440]
[2.671, 9.172]
[1.420, 12.997]
[0.603, 1.243]
[0.987, 1.861]
[0.621, 3.407]
[1.048, 2.769]
[0.560, 1.458]
[1.350, 2.740]
[0.969, 1.879]
[0.361, 1.430]
[1.069, 1.711]
[1.279, 50.040]
[1.215, 5.407]
[0.533, 1.623]
[0.787, 4.461]
[1.003, 2.399]
 0.50  1.0  2.0  4.0  8.0 16.0
odds ratio (headache relief)
FIGURE 1 Forest plot for the migraine example data introduced in Sec. 3. The last three studies (Ueberall (1999), Hämäläinen
(2002) andHo (2012)) are the paediatric ones of primary interest, while the top 20 studies are the adolescents’ studies constituting
the external information that may potentially be extrapolated. The endpoint of interest here is the odds ratio of headache relief
for triptans vs. placebo. The combined estimate here is based on the 2-component model with 푝(푀1) = 0.5 (see also row VII in
Fig. 4 ).
analysis model setup via the specification of prior probabilities
푝(푀푖) for the different model components.
The data are in the following analyzed using a mixture of
two components, considering the cases of “complete pooling”
(푀1), and of two “standalone” analyses (푀4). A priori, we
assume a probability of 푝(푀1) = 0.5 for the joint model, and
푝(푀4) = 0.5 for unrelated effects in adolescents and adults.
With a substantial amount of scepticism associated with the
prior information, we consider this a conservative choice44.
We will also consider alternative prior setups later on.
The two components as well as the resulting mixture prior
for the effect (휇) are also shown in Fig. 2 (left panel). The
vague component (according to Sec. 2.4.3) is normal with zero
mean and standard deviation of 2. The informative component
results as the posterior from the analysis of the adolescents’
data (see Sec. 3.1).
3.3 Analysis results
Analysis of the children’s data under the two prior compo-
nents yields a Bayes factor of 5.1 in favour of the “pooling”
model (푀1). Given our prior specifications, this implies a pos-
terior probability of 푝(푀1|푦) = 0.837 for the joint model.
Technically, the effect’s posterior distribution then results as a
correspondingly weighted mixture of the two conditional pos-
teriors 푝(휇|푦,푀푖); these are also shown in Fig. 2 (right panel),
where one can see how the posterior mixture here turns out
to be dominated by the “informative” conditional 푝(휇|푦,푀1).
The estimated effect then is at an OR of 1.402, with a 95%
credible interval of [1.003, 2.399]. The estimate is also shown
along with the data in Fig. 1 . The R code to reproduce these
results is available in the Appendix.
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FIGURE 2 Prior (left) and posterior (right) densities for the example from Sec. 3. The left panel shows the prior along with
its two (informative and vague) mixture components. The right panel shows the posterior, which again is a mixture of two
(conditional) posteriors. The shaded area indicates the posterior 95% CI.
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FIGURE 3 Diagnostic plots showing the effect of varying the prior probability 푝(푀1) (left panel) and the vague prior standard
deviation
√
Var(휇|푀4) (right panel) in the migraine example from Sec. 3. The solid blue line shows the resulting effect estimate
(log-OR), the shaded area indicates the corresponding 95% CI. The dashed green lines indicate a prior 95% range.
3.4 Sensitivity analyses
3.4.1 Varying model probabilities
We may now also investigate the effect of changing the prior
probability 푝(푀1) expressing the a priori expectations of
whether and how the two data sources may be aggregated.
Fig. 3 (left panel) illustrates the resulting effect estimates
(log-OR) and credible intervals when varying the prior proba-
bility 푝(푀1). In the extreme cases of 푝(푀1)=1 and 푝(푀1)=0,
we are left with the simple models of “complete pooling” (푀1)
and two separate “standalone analyses” (푀4), respectively. In
between, we can see how the estimate is more or less “shrunk”
towards the pooled estimate, and as long as 푝(푀1) ≥ 0.5, the
credible interval indicates a positive treatment effect.
3.4.2 Varying the vague prior specification
Besides varying the models’ prior weight via 푝(푀1), we can
also investigate the effect of different specifications of the
effect’s prior standard deviation (as defined in Sec. 2.4.3) by
varying it from its initial value of 2. Fig. 3 (right panel)
illustrates the effect on the log-OR estimate and credible inter-
val. As expected, a very small standard deviation eventually
shrinks the estimate towards the priormean (left side). For very
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I.
II.
III.
IV.
V.
VI.
VII.
VIII.
IX.
X.
XI.
XII.
XIII.
components
1
2
3
4
p(M1)
100
0
0
0
25
50
75
25
50
75
25
50
75
p(M2)
0
100
0
0
0
0
0
0
0
0
25
17
8
p(M3)
0
0
100
0
0
0
0
38
25
12
25
17
8
p(M4)
0
0
0
100
75
50
25
38
25
12
25
17
8
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FIGURE 4 Analyses of the migraine data using different prior weights 푝(푀푖) (in percent) for the model components (푀1
= “complete pooling”, 푀2 = “effect-only pooling”, 푀3 = “heterogeneity-only pooling”, 푀4 = “standalone analyses”). The
resulting posterior model probabilities 푝(푀푖|푦) as well as corresponding estimate and CI of the OR are shown.
large variances, one can see the effect of Lindley’s paradox (see
Sec. 2.3): the marginal likelihood of the paediatric data under
푀4 decreases, and the “pooling” component푀1 dominates the
posterior.
The current setting of a standard deviation of 2 corresponds
to a priori 95% probability roughly within a range of odds
ratios between 1
50
and 50. Varying the range of ORs by a fac-
tor of two (25 or 100 instead of 50) would correspond to prior
standard deviations of 1.64 or 2.35, respectively. Doubling the
standard deviation to a value of 2 would correspond to an
increase of the prior range up to values of 502=2500 already,
so the range of plausible values is probably not too far from 2.
3.4.3 Considering more than two components
One may consider more than two components in the model,
in order to account for the possibility of a different associa-
tion between adolescents’ and children’s data. Fig. 4 presents
the resulting estimates for a range of models with only a sin-
gle or up to four components. The first columns show the prior
and resulting posterior probabilities (푝(푀푖) and 푝(푀푖|푦)) for
the different model components. RowVI shows the results dis-
cussed in Sec 3.3, while rows I, IV, V and VII are among the
estimates also shown in Fig. 3 (left panel).
One can see that the results based on parameter models푀1
and 푀2 as well as those for 푀3 and 푀4 (first four rows) are
very similar. Based on the given data, it seems hard to distin-
guish between these pairs of models; when given equal prior
probabilities, the posterior probabilities tend to be similar as
well, as one can see e.g. in row XI; using only components
푀1 and푀4 instead leads to a very similar estimate (row VI).
Again, as soon as 푝(푀1)≥0.5, all credible intervals indicate a
positive effect estimate.
4 PAEDIATRIC TRANSPLANTATION
CASE STUDY
4.1 Background
The data considered in the following example are from Goral-
czyk et al.45 and Crins et al.46, and these illustrate a case of an
apparent prior/data conflict. Both studies were meta-analyses
investigating the effect of Interleukin-2 receptor antagonists
(IL-2RA) on the reported frequencies of acute rejection (AR)
reactions after liver transplantation. Both reviews included
controlled studies; here we focus on the subset of randomized
controlled trials. The earlier publication45 was concerned with
adults, while the more recent publication46 was on paediatric
patients. Tab. B2 in the Appendix shows the relevant data
(numbers of cases and events, and derived ORs) of 16 ran-
domized studies; the effect sizes are also illustrated in Fig. 5 .
Considering the case of paediatric liver transplantation, there
are only two studies available. Given the present body of evi-
dence based on adult patients (14 studies), where the immune
reaction may be similar, it is of interest to allow for this addi-
tional data to possibly inform the meta-analysis of the two
paediatric studies.
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publication
Washburn (2001)
Neuhaus (2002)
Yan (2004)
Boillot (2005)
Fasola (2005)
Yoshida (2005)
de Simone (2007)
Kato, cohort 1 (2007)
Kato, cohort 2 (2007)
Klintmalm (2007)
Schmeding (2007)
Lupo (2008)
Neuberger (2009)
Calmus (2010)
  adults only
Heffron (2003)
Spada (2006)
  children only
  children combined
subjects
adults
adults
adults
adults
adults
adults
adults
adults
adults
adults
adults
adults
adults
adults
children
children
OR
1.000
0.775
0.238
0.942
0.466
0.810
0.768
0.681
0.433
0.786
1.213
0.455
0.547
0.984
0.769
0.099
0.284
0.184
0.188
95% CI
[0.057, 17.621]
[0.515, 1.164]
[0.055, 1.030]
[0.671, 1.321]
[0.167, 1.301]
[0.386, 1.698]
[0.376, 1.569]
[0.165, 2.804]
[0.095, 1.980]
[0.454, 1.360]
[0.549, 2.678]
[0.109, 1.890]
[0.322, 0.929]
[0.511, 1.893]
[0.618, 0.949]
[0.031, 0.322]
[0.081, 1.000]
[0.065, 0.538]
[0.071, 0.734]
0.05 0.10 0.20 0.50 1.00 2.00
odds ratio (acute rejection)
FIGURE 5 Forest plot for the transplantation data discussed in Sec. 4. The last two studies (Heffron (2003) and Spada (2006))
are the paediatric ones that are in the focus of the investigation, while the top 14 studies are based on adults and constitute the
external information that may (potentially) be extrapolated. The endpoint of interest here is the number of acute rejection events.
The combined estimate here is based on the 2-component model with 푝(푀1) = 0.5.
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FIGURE 6 Prior (left) and posterior (right) densities for the example from Sec. 4. The left panel shows the prior along with
its two (informative and vague) mixture components. The right panel shows the posterior, which again is a mixture of two
(conditional) posteriors. The shaded area indicates the posterior 95% CI.
4.2 Analysis setup and results
We use an analogous setup as in the previous analysis and con-
sider the two models 푀1 and 푀4. The prior used to analyze
the paediatric data again is a heavy-tailed mixture of a vague
component (as described in Sec. 3.2) and the posterior derived
from the adult data. The weight of the informative prior com-
ponent again is taken to be 푝(푀1) = 0.5. From the adults’ data
alone we get posterior mean and standard deviation for 휇 of
-0.266 and 0.109, respectively; the estimate and 95% CI for
the OR is 0.769 [0.618, 0.949]. The resulting prior as well as
conditional and marginal posteriors are illustrated in Fig. 6 .
The circumstances here differ from the previous example, as
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FIGURE 7 Diagnostic plot showing the effect of varying the
prior probability 푝(푀1) on the resulting effect estimate (pos-
terior median and CI) in the transplantation example from
Sec. 4.
the paediatric data now look rather different from the external
source data: we observe a larger effect (greater reduction of
rejection reactions) in children than in adults (see Fig. 5 ).
Although a priori we would tend to assume that we might
also analyse the data jointly (푝(푀1) = 0.5), the data lead us to
revise our view (푝(푀1|푦) = 0.031); the Bayes factor here is at
30.9 in favour of the “standalone analysis” model (푀4). Fig. 7
illustrates the effect of varying the prior certainty 푝(푀1): one
can see that the “pooling” model (푀1) is heavily discounted
unless one had a very strong prior in its favour (say, 푝(푀1) >
95%). Including the possibility of푀1 heremostly has the effect
of widening the posterior to include the range suggested by the
external data, and only an extremely strong prior confidence
will actually shrink the posterior towards complete pooling.
Effectively this leads to more cautious conclusions, including
the possibility of a less pronouced effect as suggested by the
external information. Based on this analysis we get an estimate
and 95% CI for the OR in children of 0.188 [0.071, 0.734].
5 SIMULATION STUDY
5.1 Simulation setup
In order to gain more insight into the behaviour of the extrapo-
lation model, we run simulations reflecting the four parameter
models considered. We use three or ten (푘S ∈ {3, 10}) source
studies with 휇S = 0.25 and 휏S = 0.2. Of primary inter-
est are three (푘T = 3) target studies with equal or different
parameters 휇T and 휏T as shown in Tab. 1 . Estimates 푦푖 are
TABLE 1 The parameter values used in the four simula-
tion scenarios (푆1–푆4, corresponding to models푀1–푀4) dis-
cussed in Sec. 5. The boldface figures indicate the parameters
that differ between source and target.
source target
parameters parameters
scenario (model) 휇S 휏S 휇T 휏T
푆1 (푀1) 0.25 0.2 0.25 0.2
푆2 (푀2) 0.25 0.2 0.25 0.5
푆3 (푀3) 0.25 0.2 1.0 0.2
푆4 (푀4) 0.25 0.2 1.0 0.5
generated (according to the model, see Sec. 2.1) on a con-
tinuous scale, and standard errors (푠푖) are drawn uniformly
between 0.2 and 1.0; for binary (log-OR) outcomes, this
roughly corresponds to sample sizes between 16 and 400.
We then investigate resulting coverages and mean widths of
95% CIs based on 10 000 replications each for each scenario,
yielding a simulation error of 0.22 percentage points for the
coverages.
In order to check validity of our computations, we also
generated data sets with parameters drawn from the prior dis-
tribution and checked for proper coverage of the resulting
credible intervals, which should be exact by construction47,48.
Data were generated based on parameters drawn from the
vague prior distribution, either independently or identically for
target and source data with probability 0.5, corresponding to
the setting used e.g. in Sec. 3.2.
5.2 Simulation results
CI coverages and widths for 푘S=10 source studies are shown
in Tab. 2 . As expected, “naïve” extrapolation based only on
model푀1 fails especially in scenarios푆3 and푆4 (row I), while
a standalone analysis of the target data only yields proper cov-
erage, but at the cost of much wider CIs (model푀4, row IV).
Combining several prior components to a mixture then allows
to gain in CI width, while coverage probability is slightly
reduced in case of a prior/data (source/target) conflict. Again,
we know that on average over the corresponding prior distri-
bution, the coverage will be at exactly 95% by construction.
Coverage is above the nominal 95% in scenario 푆1 as well as
the very similar 푆2, and it is lower in scenarios 푆3 and 푆4.
As already apparent in the example application in Sec. 3,
due to the limited amount of data considered, models 푀1
and 푀2 as well as models푀3 and푀4 are barely distinguish-
able. Tab. C3 (see Appendix) shows that (e.g. in row XI),
when the pairs of models have equal prior probabilities, the
resulting posterior probabilities tend to be very similar as well,
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TABLE 2 Coverage (%), and CI width in the four simulation scenarios (푆1–푆4) and using a number of analysis settings
(differing numbers of studies as well as differing prior settings; similar to Fig. 4 ).
# studies prior 푝(푀푖) (%) 푆1 푆2 푆3 푆4
(푘S + 푘T) 푀1 푀2 푀3 푀4 coverage width coverage width coverage width coverage width
10 + 3 I. 100 0 0 0 97.1 (0.66) 96.0 (0.69) 10.8 (0.73) 15.6 (0.77)
IV. 0 0 0 100 98.7 (1.59) 95.0 (1.67) 98.7 (1.59) 94.5 (1.67)
V. 25 0 0 75 99.6 (1.29) 97.5 (1.41) 95.4 (1.53) 89.7 (1.59)
VI. 50 0 0 50 99.5 (1.06) 97.9 (1.19) 89.5 (1.45) 81.9 (1.50)
VII. 75 0 0 25 98.8 (0.86) 97.9 (0.98) 76.4 (1.33) 70.4 (1.38)
VIII. 25 0 38 38 99.3 (1.25) 96.8 (1.35) 94.8 (1.47) 88.1 (1.52)
IX. 50 0 25 25 99.4 (1.04) 97.6 (1.16) 89.0 (1.41) 80.5 (1.45)
X. 75 0 12 12 98.8 (0.85) 97.7 (0.97) 76.2 (1.31) 69.2 (1.35)
XI. 25 25 25 25 99.5 (1.05) 98.3 (1.15) 89.3 (1.44) 80.5 (1.48)
XII. 50 17 17 17 99.0 (0.92) 98.0 (1.03) 81.7 (1.37) 73.7 (1.40)
XIII. 75 8 8 8 98.5 (0.79) 97.6 (0.89) 68.6 (1.26) 63.3 (1.30)
3 + 3 I. 100 0 0 0 98.1 (1.06) 96.2 (1.12) 77.5 (1.16) 74.9 (1.22)
IV. 0 0 0 100 98.7 (1.59) 95.0 (1.67) 98.7 (1.59) 94.5 (1.67)
V. 25 0 0 75 99.1 (1.42) 96.6 (1.51) 97.3 (1.54) 92.8 (1.61)
VI. 50 0 0 50 99.1 (1.29) 96.8 (1.38) 95.2 (1.49) 90.0 (1.56)
VII. 75 0 0 25 98.7 (1.18) 96.7 (1.27) 91.2 (1.42) 86.2 (1.48)
VIII. 25 0 38 38 99.0 (1.40) 96.2 (1.49) 97.1 (1.52) 92.4 (1.59)
IX. 50 0 25 25 99.0 (1.28) 96.7 (1.37) 95.0 (1.48) 89.8 (1.54)
X. 75 0 12 12 98.7 (1.18) 96.7 (1.26) 91.2 (1.41) 86.0 (1.47)
XI. 25 25 25 25 99.1 (1.28) 96.9 (1.36) 95.0 (1.49) 89.7 (1.55)
XII. 50 17 17 17 98.9 (1.21) 96.8 (1.30) 92.6 (1.44) 87.3 (1.50)
XIII. 75 8 8 8 98.6 (1.14) 96.6 (1.22) 89.1 (1.38) 84.1 (1.44)
i.e., the corresponding Bayes factors are close to unity. The
model similarity is also evident in the resulting estimates when
comparing e.g. rows VI, IX and XI in Tab. 2 or Fig. 4 .
In addition to the simulations with 푘S=10 “source” studies,
we also investigated the performance for a smaller external evi-
dence base of only 푘S = 3 studies. The behaviour with respect
to CI coverage and length is qualitatively similar, but not quite
as pronounced. Regarding the posterior probabilities 푝(푀푖|푦)
(Tab. C3 in the Appendix) it is apparent that these are mostly
determined by the prior probabilities and less affected by the
data. Based on the little data only, the models apparently are
hardly distinguishable, and consequently extra care should be
taken to specify priors reasonably.
In the 10 000 simulations with parameter values drawn from
the 2-component mixture prior, 94.96% of credible intervals
covered the true parameter values in the setting of 푘S+푘T =
10+3 studies, and coverage was at 95.08% for 푘S+푘T = 3+3
studies, which in both cases is within the range expected for a
nominal 95% coverage. This was expected by construction of
the CI, as mentioned above.
6 DISCUSSION
Mixture priors provide a means to support an analysis using
external information in a robust manner24. We have showcased
in two examples how the approach may easily be implemented
in evidence synthesis by utilizing the simplicity of the mix-
ture model, which implies that the posterior again constitutes
a model average, a weighted mixture of the conditional pos-
teriors based on the prior components. In the meta-analysis
context, this means that off-the-shelf software may be used to
perform the main computations, which then only need to be
re-combined. MCMC methods only become necessary when
a 4-component model is desired. The resulting procedure pro-
vides a transparent and robust data-driven approach to analysis
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that has the potential to either boost or discount relevant prior
information, depending on its apparent compatibility.
The examples discussed here were intentionally restricted to
simple random-effects meta-analysis with log-odds ratio end-
points. The same approach is readily extended to other types
of endpoints that are conventionally analyzed using a random-
effects model. The main point here was primarily to demon-
strate the approach of using heavy-tailed23 or mixture priors24,
its simplicity and its potential. More generally, the approach
demonstrated here shows a way of overcoming the bayesmeta
package’s restriction to normal effect priors, which is due to the
semi-analytic implementation40,49. Robust priors for the het-
erogeneity parameter may already be implemented by simply
using e.g. heavy-tailed half-Student-푡, half-Cauchy, or Lomax
distributions.
When looking for example at themeta-analyses published in
the Cochrane library, a large number of investigations include
additional analyses of pre-defined subgroups of studies in addi-
tion to an overall estimate41. Such cases are examples in which
there may be a benefit from borrowing of information on
effect or heterogeneity. The obvious danger here is that, being
presented with subgroup as well as overall estimates, the prac-
titioner may effectively perform the extrapolation in a rather
intransparent manner based on eyeballing data and estimates.
While the use of two prior components may often be rea-
sonable and sufficient, the setup has the disadvantage that
prior/data conflict is confounded for effect and heterogene-
ity. Extending to more general formulations including more
components may provide some more flexibility, if desired.
However, the simulations showed that slight model variations
may not be distinguishable or may not make a noticeable dif-
ference if data are sparse. Based on the principle of parsimony
(Occam’s razor), one may then want to give preference to
simpler, sparser model formulations.
In a Bayesian analysis, proper coverage of credible intervals
is, by construction, guaranteed conditional on the prior distri-
bution; this implies that the long-run coverage will be exact
if the data-generating parameter values are repeatedly drawn
from the prior distribution48. However, coverage probability is
not necessarily at the nominal level when data are generated
repeatedly based on single constant parameter values (which
is the common frequentist requirement50). By constructing the
prior as informative, and complementing the informative prior
with a “robustifying” vague component, we expect the cov-
erage to exceed the nominal credible level when conditioning
on the informative component only, and to be lower condi-
tional on the vague component. As usual, inferences will be
reasonable and consistent when model and prior are speci-
fied sensibly; in the present case it is especially crucial to also
specify the vague prior component realistically. In contrast to
immediate intuition, a larger prior variance is not necessar-
ily a more conservative choice, due to Lindley’s paradox. In
order to enhance robustness, the prior probability of the vague
component should be increased instead.
Many other variations of the approach are conceivable. The
external information does not necessarily need to come from a
secondmeta-analysis, but could also be based on other types of
data. Likewise, the “main” analysis does not need to be a meta-
analysis, but could also be a single study with a meta-analysis
informing the prior, which would lead to an approach very
similar to the original setup discussed by Schmidli et al.24.
The presented approach however is no substitute for a care-
ful check of appropriateness of possible data pooling. Note that
in the transplantation example a joint analysis may already be
highly questionable on theoretical grounds. While in the pre-
ceding migraine example, it is conceivable that with adjusted
dosing a comparable effect may be achieved in adolescents and
children, in the transplantation context, indications and surgi-
cal practice differ between adults and children in a range of
aspects, so that a similarity of effect may already be doubtful
a priori. Even if the different data themselves may not be obvi-
ously contradicting, pooling always also requires a theoretical
justification, and plausibility should be reflected in the model
setup (here especially in the weighting of prior components).
ACKNOWLEDGMENTS
The authors wish to thank Beat Neuenschwander and Heinz
Schmidli for helpful comments. This research has received
funding from the EU’s 7th Framework Programme for
research, technological development and demonstration under
grant agreement number FP HEALTH 2013-602144 with
project title (acronym) “Innovative methodology for small
populations research” (InSPiRe).
Author contributions
CR, SW and TF conceived the concept of this study, CR con-
ducted all numerical evaluations for the examples and the
simulations, and drafted the manuscript. TF and SW critically
reviewed andmade substantial contributions to themanuscript.
All authors commented on and approved the final manuscript.
Financial disclosure
FPHEALTH 2013-602144“Innovativemethodology for small
populations research” (InSPiRe).
12 C. RÖVER, S. WANDEL, T. FRIEDE
Conflict of interest
Tim Friede and Christian Röver declare no conflict of interest.
SimonWandel is employed by Novartis Pharma AG, and owns
stocks thereof.
C. RÖVER, S. WANDEL, T. FRIEDE 13
How to cite this article: C. Röver, S. Wandel, and T. Friede
(2017), Model averaging for robust extrapolation in evidence
synthesis, Statistics in Medicine, 2018;00:0–0.
APPENDIX
AMIXTURE POSTERIOR DERIVATION
Consider a setup where the prior distribution is a two-
component mixture
푝(휗) = 푝(휗|푀푎) 푝(푀푎) + 푝(휗|푀푏) 푝(푀푏) (A1)
and interest lies in determining the posterior 푝(휗|푦) based on
data 푦 and some likelihood function 푝(푦|휗). The parameters’
posterior distribution then is given by
푝(휗|푦) = 푝(푦|휗) 푝(휗)∫ 푝(푦|휗) 푝(휗) d휗 (A2)
=
푝(푦|휗) (푝(휗|푀푎) 푝(푀푎) + 푝(휗|푀푏) 푝(푀푏)
)
∫ 푝(푦|휗) (푝(휗|푀푎) 푝(푀푎) + 푝(휗|푀푏) 푝(푀푏)) d휗 (A3)
=
푝(푀푎) 푝(푦|휗) 푝(휗|푀푎) + 푝(푀푏) 푝(푦|휗) 푝(휗|푀푏)
푝(푀푎) ∫ 푝(푦|휗) 푝(휗|푀푎) d휗 + 푝(푀푏) ∫ 푝(푦|휗) 푝(휗|푀푏) d휗(A4)
=
푝(푀푎) 푝(푦|휗) 푝(휗|푀푎) + 푝(푀푏) 푝(푦|휗) 푝(휗|푀푏)
푝(푀푎) 푝(푦|푀푎) + 푝(푀푏) 푝(푦|푀푏)
(A5)
=
푝(푀푎) 푝(푦|휗) 푝(휗|푀푎)
푝(푀푎) 푝(푦|푀푎) + 푝(푀푏) 푝(푦|푀푏)
(A6)
+
푝(푀푏) 푝(푦|휗) 푝(휗|푀푏)
푝(푀푎) 푝(푦|푀푎) + 푝(푀푏) 푝(푦|푀푏)
(A7)
=
푝(푦|휗) 푝(휗|푀푎)
푝(푦|푀푎)
푝(푀푎) 푝(푦|푀푎)
푝(푀푎) 푝(푦|푀푎) + 푝(푀푏) 푝(푦|푀푏)
+
푝(푦|휗) 푝(휗|푀푏)
푝(푦|푀푏)
푝(푀푏) 푝(푦|푀푏)
푝(푀푎) 푝(푦|푀푎) + 푝(푀푏) 푝(푦|푀푏)
(A8)
= 푝(휗|푦,푀푎) 푝(푀푎|푦) + 푝(휗|푦,푀푏) 푝(푀푏|푦), (A9)
which again is a mixture of the two conditional posterior
distributions 푝(휗|푦,푀푎) and 푝(휗|푦,푀푏).
B EXAMPLE DATA
Tab. B1 shows the paediatric migraine example data due to
Richer et al.43, which are discussed in Sec. 3. The paediatric
transplantation example data due to Crins et al.46, which are
used in Sec. 4, are shown in Tab. B2 .
C ADDITIONAL SIMULATION RESULTS:
MODEL PROABILITIES
Tab. C3 below shows the average model probabilities corre-
sponding to the simulation results shown in Tab. 2 (Sec. 5).
D EXAMPLE R CODE
D.1 Two-component mixture
The following R code allows to reproduce the analysis from
Sec. 3. In addition to R27, the metafor51 and bayesmeta28,40
packages are required. The other analyses are done completely
analogously.
# read data:
RicherEtAl2016 <- read.csv("RicherEtAl2016.csv",
colClasses=c("study"="character"))
# compute effect sizes (log-ORs):
require("metafor")
effsize <- escalc(measure="OR",
ai=triptan.events, n1i=triptan.total,
ci=placebo.events, n2i=placebo.total,
slab=study, data=RicherEtAl2016)
# specify subset indices:
aidx <- (effsize[,"patients"]=="adolescents")
cidx <- (effsize[,"patients"]=="children")
########################
# main MA computations:
require("bayesmeta")
# standard deviation of vague prior:
vaguepriorsd <- 2
# meta analysis for adolescents only:
bma.adol <- bayesmeta(effsize[aidx,],
mu.prior.mean=0, mu.prior.sd=vaguepriorsd,
tau.prior=function(t){dhalfnormal(t,scale=0.5)})
# meta analysis for children only:
bma.child <- bayesmeta(effsize[cidx,],
mu.prior.mean=0, mu.prior.sd=vaguepriorsd,
tau.prior=function(t){dhalfnormal(t,scale=0.5)})
# joint meta analysis for all patients:
bma.joint <- bayesmeta(effsize,
mu.prior.mean=0, mu.prior.sd=vaguepriorsd,
tau.prior=function(t){dhalfnormal(t,scale=0.5)})
# assemble marginal likelihoods:
marginals <- c("M1: pooled" = bma.joint$marginal,
"M4: separate" = bma.adol$marginal
* bma.child$marginal)
print(marginals)
barplot(marginals, ylab="marginal likelihood")
# Bayes factor:
bf <- marginals[1] / marginals[2]
print(c("M1: pooled"=unname(bf), "M4: separate"=1/unname(bf)))
# specify prior (p(M1)):
prior.prob <- 0.50
prior.odds <- prior.prob / (1-prior.prob)
# determine posterior:
post.odds <- prior.odds * bf
post.prob <- post.odds / (post.odds+1)
print(post.prob)
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TABLEB1 Data set due to Richer et al.43; the numbers of events and total numbers of patients in treatment and control groups
are shown along with the corresponding derived logarithmic odds ratios (log-ORs) and confidence intervals.
patient triptan placebo log-OR
publication type group group (95% CI)
Hämäläinen (1997b) adolescents 7 / 23 5 / 23 0.454 [-0.876, 1.785]
Rothner (1997) adolescents 113 / 226 46 / 74 -0.496 [-1.034, 0.041]
Winner (1997) adolescents 111 / 222 32 / 76 0.318 [-0.207, 0.844]
Rothner (1999a) adolescents 96 / 186 20 / 34 -0.292 [-1.033, 0.449]
Rothner (1999b) adolescents 17 / 62 7 / 30 0.216 [-0.797, 1.230]
Rothner (1999c) adolescents 23 / 66 14 / 36 -0.174 [-1.014, 0.666]
Winner (2000) adolescents 243 / 377 69 / 130 0.472 [0.068, 0.876]
Winner (2002) adolescents 98 / 149 80 / 142 0.398 [-0.076, 0.872]
Ahonen (2004) adolescents 53 / 83 32 / 83 1.035 [0.406, 1.664]
Visser (2004a) adolescents 159 / 233 165 / 240 -0.024 [-0.412, 0.364]
Ahonen (2006) adolescents 71 / 96 35 / 96 1.599 [0.982, 2.216]
Evers (2006) adolescents 18 / 29 8 / 29 1.458 [0.350, 2.565]
Rothner (2006) adolescents 262 / 480 93 / 160 -0.144 [-0.506, 0.218]
Winner (2006) adolescents 316 / 483 141 / 242 0.304 [-0.013, 0.621]
Callenbach (2007) adolescents 19 / 46 15 / 46 0.375 [-0.477, 1.226]
Lewis (2007) adolescents 97 / 148 67 / 127 0.533 [0.046, 1.019]
Winner (2007) adolescents 82 / 144 79 / 133 -0.101 [-0.579, 0.377]
Linder (2008) adolescents 383 / 544 94 / 170 0.654 [0.300, 1.008]
Ho (2012) adolescents 167 / 284 147 / 286 0.300 [-0.031, 0.631]
Fujita (2014) adolescents 23 / 74 27 / 70 -0.331 [-1.019, 0.357]
Ueberall (1999) children 12 / 14 6 / 14 2.079 [0.246, 3.913]
Hämäläinen (2002) children 38 / 59 24 / 58 0.941 [0.195, 1.688]
Ho (2012) children 53 / 98 57 / 102 -0.073 [-0.630, 0.485]
# show prior & posterior probabilities:
print(matrix(c(prior.prob, 1-prior.prob,
post.prob, 1-post.prob),
nrow=2, ncol=2, byrow=TRUE,
dimnames=list(c("prior","posterior"),
c("M1: pooled","M4: separate"))))
##############################################################
# functions to compute cumulative distribution function etc.:
# cumulative distribution function (CDF):
cdf <- function(mu=0, prob = post.prob)
{
dens <- function(x)
{
return(prob*bma.joint$dposterior(mu=x)
+ (1-prob)*bma.child$dposterior(mu=x))
}
integral <- integrate(dens, lower=-Inf, upper=mu)
return(integral$value)
}
# quantile function (inverse CDF):
invcdf <- function(p, xrange=c(-4,4), prob=post.prob)
{
if ((cdf(xrange[1], prob=prob)<p)&(cdf(xrange[2], prob=prob)>p))
result <- uniroot(function(x){cdf(x, prob=prob)-p},
lower=xrange[1], upper=xrange[2])$root
else
result <- NA
return(result)
}
# function to determine shortest credible interval:
shortest.interval <- function(level=0.95,
min.p=0.001, prob=post.prob)
{
intwidth <- function(left)
{
pleft <- cdf(left, prob=prob)
right <- invcdf(level+pleft, prob=prob)
return(right-left)
}
opti <- optimize(intwidth, lower=invcdf(min.p, prob=prob),
upper=invcdf(1-level, prob=prob))$minimum
result <- c(opti, invcdf(level+cdf(opti, prob=prob), prob=prob))
return(result)
}
########################################################
# compute eventual estimates (median and 95% interval):
# median & credible interval:
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TABLE B2 Data set due to Goralczyk et al.45 and Crins et al.46. The numbers of events and total numbers of patients in
treatment and control groups are shown along with the corresponding derived odds ratios (ORs) and confidence intervals.
patient IL-2RA control odds ratio
publication type group group (95% CI)
Washburn (2001) adults 1 / 15 1 / 15 1.000 [0.057, 17.62]
Neuhaus (2002) adults 74 / 188 88 / 193 0.775 [0.515, 1.164]
Yan (2004) adults 3 / 24 9 / 24 0.238 [0.055, 1.030]
Boillot (2005) adults 89 / 351 92 / 347 0.942 [0.671, 1.321]
Fasola (2005) adults 13 / 46 11 / 24 0.466 [0.167, 1.301]
Yoshida (2005) adults 17 / 72 21 / 76 0.810 [0.386, 1.698]
de Simone (2007) adults 17 / 95 21 / 95 0.768 [0.376, 1.569]
Kato, cohort 1 (2007) adults 7 / 15 9 / 16 0.681 [0.165, 2.804]
Kato, cohort 2 (2007) adults 3 / 16 8 / 23 0.433 [0.095, 1.980]
Klintmalm (2007) adults 80 / 153 46 / 79 0.786 [0.454, 1.360]
Schmeding (2007) adults 29 / 51 25 / 48 1.213 [0.549, 2.678]
Lupo (2008) adults 4 / 26 6 / 21 0.455 [0.109, 1.890]
Neuberger (2009) adults 28 / 168 45 / 168 0.547 [0.322, 0.929]
Calmus (2010) adults 23 / 98 24 / 101 0.984 [0.511, 1.893]
Heffron (2003) children 14 / 61 15 / 20 0.099 [0.031, 0.322]
Spada (2006) children 4 / 36 11 / 36 0.284 [0.081, 1.000]
TABLE C3 Average posterior model probabilities 푝(푀푖|푦) (in %) in the four simulation scenarios (푆1–푆4).
# studies prior 푝(푀푖) (%) 푆1 푆2 푆3 푆4
(푘S + 푘T) 푀1 푀2 푀3 푀4 푀1 푀2 푀3 푀4 푀1 푀2 푀3 푀4 푀1 푀2 푀3 푀4 푀1 푀2 푀3 푀4
10 + 3 V. 25 0 0 75 55 0 0 45 48 0 0 52 27 0 0 73 27 0 0 73
VI. 50 0 0 50 77 0 0 23 70 0 0 30 46 0 0 54 45 0 0 55
VII. 75 0 0 25 90 0 0 10 86 0 0 14 65 0 0 35 62 0 0 38
VIII. 25 0 38 38 54 0 23 23 48 0 25 27 27 0 38 36 27 0 36 37
IX. 50 0 25 25 76 0 12 12 70 0 14 15 46 0 28 27 45 0 27 28
X. 75 0 12 12 90 0 5 5 86 0 7 7 64 0 18 17 62 0 18 19
XI. 25 25 25 25 39 37 12 12 35 36 14 14 23 24 27 26 22 25 26 26
XII. 50 17 17 17 65 20 7 7 60 21 9 9 43 16 21 20 41 17 21 21
XIII. 75 8 8 8 85 9 3 3 81 10 5 5 64 8 14 13 62 9 15 15
3 + 3 V. 25 0 0 75 48 0 0 52 45 0 0 55 32 0 0 68 31 0 0 69
VI. 50 0 0 50 72 0 0 28 69 0 0 31 53 0 0 47 52 0 0 48
VII. 75 0 0 25 88 0 0 12 86 0 0 14 73 0 0 27 71 0 0 29
VIII. 25 0 38 38 48 0 26 26 45 0 27 28 31 0 35 34 31 0 34 35
IX. 50 0 25 25 72 0 14 14 69 0 15 16 53 0 24 23 52 0 24 24
X. 75 0 12 12 88 0 6 6 86 0 7 7 72 0 14 14 71 0 14 14
XI. 25 25 25 25 37 35 14 14 35 35 15 15 26 27 23 23 26 27 23 24
XII. 50 17 17 17 63 20 8 8 60 20 10 10 49 17 17 17 48 17 17 17
XIII. 75 8 8 8 83 9 4 4 81 9 5 5 71 8 10 10 70 8 11 11
esti <- c("median" = invcdf(0.5, prob=post.prob),
"lower" = NA, "upper" = NA)
# shortest interval:
esti[2:3] <- shortest.interval(prob=post.prob)
print(esti)
print(exp(esti))
D.2 Three-component mixture
The following R code allows to reproduce the analysis shown
in row IX. of Fig. 4 , using a 3-component mixture for the
prior.
# read data:
RicherEtAl2016 <- read.csv("RicherEtAl2016.csv",
colClasses=c("study"="character"))
# compute effect sizes (log-ORs):
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require("metafor")
effsize <- escalc(measure="OR",
ai=triptan.events, n1i=triptan.total,
ci=placebo.events, n2i=placebo.total,
slab=study, data=RicherEtAl2016)
# subset indices:
aidx <- (effsize[,"patients"]=="adolescents")
cidx <- (effsize[,"patients"]=="children")
########################
# main MA computations:
require("bayesmeta")
# standard deviation of vague prior:
vaguepriorsd <- 2
# meta analysis for adolescents only:
bma.adol <- bayesmeta(effsize[aidx,],
mu.prior.mean=0, mu.prior.sd=vaguepriorsd,
tau.prior=function(t){dhalfnormal(t,scale=0.5)})
# meta analysis for children only:
bma.child <- bayesmeta(effsize[cidx,],
mu.prior.mean=0, mu.prior.sd=vaguepriorsd,
tau.prior=function(t){dhalfnormal(t,scale=0.5)})
# joint meta analysis (BOTH parameters) for all patients:
bma.joint <- bayesmeta(effsize,
mu.prior.mean=0, mu.prior.sd=vaguepriorsd,
tau.prior=function(t){dhalfnormal(t,scale=0.5)})
# meta analysis for children only,
# heterogeneity prior from adolescents:
bma.child.t <- bayesmeta(effsize[cidx,],
mu.prior.mean=0, mu.prior.sd=vaguepriorsd,
tau.prior=function(t){bma.adol$dposterior(tau=t)})
# show some results
# (adolescents only / pooled / pooling tau only / children):
rbind("adolescents"=bma.adol$summary[,"mu"],
"M1: pooled"=bma.joint$summary[,"mu"],
"M3: pooled (tau only)"=bma.child.t$summary[,"mu"],
"M4: separate"=bma.child$summary[,"mu"])
# assemble marginal likelihoods:
marginals <- c("M1: pooled (mu+tau)" = bma.joint$marginal,
"M3: pooled (tau only)" = bma.adol$marginal
* bma.child.t$marginal,
"M4: separate" = bma.adol$marginal
* bma.child$marginal)
print(marginals)
barplot(marginals, ylab="marginal likelihood")
# specify prior:
prior.prob <- c("M1: pooled (mu+tau)" = 1/2,
"M3: pooled (tau only)" = 1/4,
"M4: separate" = 1/4)
# determine posterior:
post.prob <- prior.prob * marginals
post.prob <- post.prob / sum(post.prob)
# show prior & posterior probabilities:
print(round(rbind("prior"=prior.prob, "posterior"=post.prob),3))
##############################################################
# functions to compute cumulative distribution function etc.:
# cumulative distribution function (CDF):
cdf <- function(mu=0, prob = post.prob)
{
stopifnot(length(prob)==3, all(is.finite(prob)),
all(prob>=0), all(prob<=1), sum(prob)==1)
dens <- function(x)
{
return(prob[1]*bma.joint$dposterior(mu=x)
+ prob[2]*bma.child.t$dposterior(mu=x)
+ prob[3]*bma.child$dposterior(mu=x))
}
integral <- integrate(dens, lower=-Inf, upper=mu)
return(integral$value)
}
# quantile function (inverse CDF):
invcdf <- function(p, xrange=c(-4,4), prob=post.prob)
{
if ((cdf(xrange[1], prob=prob)<p)&(cdf(xrange[2], prob=prob)>p))
result <- uniroot(function(x){cdf(x, prob=prob)-p},
lower=xrange[1], upper=xrange[2])$root
else
result <- NA
return(result)
}
# function to determine shortest credible interval:
shortest.interval <- function(level=0.95,
min.p=0.001, prob=post.prob)
{
intwidth <- function(left)
{
pleft <- cdf(left, prob=prob)
right <- invcdf(level+pleft, prob=prob)
return(right-left)
}
opti <- optimize(intwidth, lower=invcdf(min.p, prob=prob),
upper=invcdf(1-level, prob=prob))$minimum
result <- c(opti, invcdf(level+cdf(opti, prob=prob), prob=prob))
return(result)
}
########################################################
# compute eventual estimates (median and 95% interval):
# median & symmetric interval:
esti <- c("median" = invcdf(0.5, prob=post.prob),
"lower" = NA, "upper" = NA)
# shortest interval (on log scale):
esti[2:3] <- shortest.interval(prob=post.prob)
print(esti)
print(exp(esti))
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